Literature DB >> 26228786

Molecular characterization of HCMV-specific immune responses: Parallels between CD8(+) T cells, CD4(+) T cells, and NK cells.

Felipe A Vieira Braga1, Kirsten M L Hertoghs1, René A W van Lier1, Klaas P J M van Gisbergen1.   

Abstract

CD8(+) T cells are important for immunity against human cytomegalovirus (HCMV). The HCMV-specific CD8(+) T-cell response is characterized by the accumulation of terminally differentiated effector cells that have downregulated the costimulatory molecules CD27 and CD28. These HCMV-specific CD8(+) T cells maintain high levels of cytotoxic molecules such as granzyme B and rapidly produce the inflammatory cytokine IFN-γ upon activation. Remarkably, HCMV-specific CD8(+) T cells are able to persist long term as fully functional effector cells, suggesting a unique differentiation pathway that is distinct from the formation of memory CD8(+) T cells after infection with acute viruses. In this review, we aim to highlight the most recent developments in HCMV-specific CD8(+) T-cell differentiation, maintenance, tissue distribution, metabolism and function. HCMV also induces the differentiation of effector CD4(+) T cells and NK cells, which share characteristics with HCMV-specific CD8(+) T cells. We propose that the overlap in differentiation of NK cells, CD4(+) and CD8(+) T cells after HCMV infection may be regulated by a shared transcriptional machinery. A better understanding of the molecular framework of HCMV-specific CD8(+) T-cell responses may benefit vaccine design, as these cells uniquely combine the capacity to rapidly respond to infection with long-term survival.
© 2015 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim.

Entities:  

Keywords:  CD4+ T cell; CD45RA+ CD8+ effector T cell; HCMV; Metabolism; NK cell; Tissue distribution

Mesh:

Substances:

Year:  2015        PMID: 26228786     DOI: 10.1002/eji.201545495

Source DB:  PubMed          Journal:  Eur J Immunol        ISSN: 0014-2980            Impact factor:   5.532


  23 in total

1.  Rapid Acquisition of Cytomegalovirus-Specific T Cells with a Differentiated Phenotype, in Nonviremic Hematopoietic Stem Transplant Recipients Vaccinated with CMVPepVax.

Authors:  Corinna La Rosa; Jeffrey Longmate; Chetan Raj Lingaraju; Qiao Zhou; Teodora Kaltcheva; Nicola Hardwick; Ibrahim Aldoss; Ryotaro Nakamura; Don J Diamond
Journal:  Biol Blood Marrow Transplant       Date:  2018-12-16       Impact factor: 5.742

2.  Epigenetic programming of T cells impacts immune reconstitution in hematopoietic stem cell transplant recipients.

Authors:  Kristine Hardy; Corey Smith; Wen Juan Tu; Robert McCuaig; Archana Panikkar; Vijayendra Dasari; Fan Wu; Siok-Keen Tey; Geoffrey R Hill; Rajiv Khanna; Sudha Rao
Journal:  Blood Adv       Date:  2018-03-27

3.  Mixed signature of activation and dysfunction allows human decidual CD8+ T cells to provide both tolerance and immunity.

Authors:  Anita van der Zwan; Kevin Bi; Errol R Norwitz; Ângela C Crespo; Frans H J Claas; Jack L Strominger; Tamara Tilburgs
Journal:  Proc Natl Acad Sci U S A       Date:  2017-12-19       Impact factor: 11.205

4.  Severe Symptomatic Primary Human Cytomegalovirus Infection despite Effective Innate and Adaptive Immune Responses.

Authors:  Raphaëlle Riou; Céline Bressollette-Bodin; David Boutoille; Katia Gagne; Audrey Rodallec; Maeva Lefebvre; François Raffi; David Senitzer; Berthe-Marie Imbert-Marcille; Christelle Retière
Journal:  J Virol       Date:  2017-02-14       Impact factor: 5.103

Review 5.  Impact of CMV upon immune aging: facts and fiction.

Authors:  Mladen Jergović; Nico A Contreras; Janko Nikolich-Žugich
Journal:  Med Microbiol Immunol       Date:  2019-04-19       Impact factor: 3.402

6.  Cellular Immune Response Induced by DNA Immunization of Mice with Drug Resistant Integrases of HIV-1 Clade A Offers Partial Protection against Growth and Metastatic Activity of Integrase-Expressing Adenocarcinoma Cells.

Authors:  Maria Isaguliants; Olga Krotova; Stefan Petkov; Juris Jansons; Ekaterina Bayurova; Dzeina Mezale; Ilze Fridrihsone; Athina Kilpelainen; Philip Podschwadt; Yulia Agapkina; Olga Smirnova; Linda Kostic; Mina Saleem; Oleg Latyshev; Olesja Eliseeva; Anastasia Malkova; Tatiana Gorodnicheva; Britta Wahren; Ilya Gordeychuk; Elizaveta Starodubova; Anastasia Latanova
Journal:  Microorganisms       Date:  2021-06-04

7.  Cytomegaloviral determinants of CD8+ T cell programming and RhCMV/SIV vaccine efficacy.

Authors:  Daniel Malouli; Scott G Hansen; Meaghan H Hancock; Colette M Hughes; Julia C Ford; Roxanne M Gilbride; Abigail B Ventura; David Morrow; Kurt T Randall; Husam Taher; Luke S Uebelhoer; Matthew R McArdle; Courtney R Papen; Renee Espinosa Trethewy; Kelli Oswald; Rebecca Shoemaker; Brian Berkemeier; William J Bosche; Michael Hull; Justin M Greene; Michael K Axthelm; Jason Shao; Paul T Edlefsen; Finn Grey; Jay A Nelson; Jeffrey D Lifson; Daniel Streblow; Jonah B Sacha; Klaus Früh; Louis J Picker
Journal:  Sci Immunol       Date:  2021-03-25

Review 8.  Mechanisms Underlying T Cell Immunosenescence: Aging and Cytomegalovirus Infection.

Authors:  Wenjuan Tu; Sudha Rao
Journal:  Front Microbiol       Date:  2016-12-27       Impact factor: 5.640

9.  Epstein-Barr Virus, but Not Cytomegalovirus, Latency Accelerates the Decay of Childhood Measles and Rubella Vaccine Responses-A 10-Year Follow-up of a Swedish Birth Cohort.

Authors:  Gintare Lasaviciute; Sophia Björkander; Claudia Carvalho-Queiroz; Ida Hed Myrberg; Bianca Nussbaum; Caroline Nilsson; Mats Bemark; Anna Nilsson; Eva Sverremark-Ekström; Shanie Saghafian-Hedengren
Journal:  Front Immunol       Date:  2017-12-21       Impact factor: 7.561

10.  The transcription factors Runx3 and ThPOK cross-regulate acquisition of cytotoxic function by human Th1 lymphocytes.

Authors:  Yasmina Serroukh; Chunyan Gu-Trantien; Baharak Hooshiar Kashani; Matthieu Defrance; Thien-Phong Vu Manh; Abdulkader Azouz; Aurélie Detavernier; Alice Hoyois; Jishnu Das; Martin Bizet; Emeline Pollet; Tressy Tabbuso; Emilie Calonne; Klaas van Gisbergen; Marc Dalod; François Fuks; Stanislas Goriely; Arnaud Marchant
Journal:  Elife       Date:  2018-02-28       Impact factor: 8.140

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.